01:42 PM EDT, 04/02/2024 (MT Newswires) -- Telo Genomics ( TDSGF ) a biotech company developing a telomere technology platform with applications measuring genomic instability in oncology, reports that patient recruitment for its minimal residual disease (MRD) clinical trial have begun. MRD refers to cancer cells that remain in the patient's system post-treatment.

So far, several patient samples have been received and processed. Telo and its collaborators at the Jewish General Hospital and McGill University have also expanded the study to include three additional prominent hospitals in the Montreal area.

Patients diagnosed with multiple myeloma at the Lakeshore Hospital, Montreal General Hospital and the Verdun Hospital will be able to participate in Telo's MRD clinical study upon undergoing bone marrow transplantation. The addition of the three hospitals has the potential to reduce patient recruitment time for the clinical study by up to 50% and increase the reliability of the trial results, the company said.

MRD testing is emerging as a promising tool in assessing treatment response and guiding therapeutic decisions in oncology.

The company's shares were last seen up C$0.01 to C$0.115 on the TSX Venture Exchange.

Price: 0.12, Change: +0.01, Percent Change: +9.52